Bank Of America Corp Atea Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 67,066 shares of AVIR stock, worth $246,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,066

Previous 243,724 72.48%

Holding current value

$246,132

Previous $743,000 63.66%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.09 - $4.56 $545,873 - $805,560	-176,658 Reduced 72.48%	67,066 $270,000
Q4 2023 Feb 14, 2024	BUY	$2.8 - $3.35 $395,399 - $473,066	141,214 Added 137.76%	243,724 $743,000
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $109,181 - $172,105	-34,013 Reduced 24.91%	102,510 $383,000
Q1 2023 May 12, 2023	SELL	$3.0 - $4.97 $113,469 - $187,980	-37,823 Reduced 21.69%	136,523 $457,000
Q4 2022 Feb 10, 2023	BUY	$4.35 - $6.17 $199,521 - $282,999	45,867 Added 35.7%	174,346 $838,000

Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $456,910 - $731,556	83,226 Added 183.91%	128,479 $731,000
Q2 2022 Aug 12, 2022	BUY	$5.33 - $8.18 $41,254 - $63,313	7,740 Added 20.63%	45,253 $321,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $477,757 - $798,289	-86,865 Reduced 69.84%	37,513 $271,000
Q4 2021 Feb 08, 2022	BUY	$7.67 - $44.59 $680,697 - $3.96 Million	88,748 Added 249.08%	124,378 $1.11 Million
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $624,307 - $1.03 Million	-29,269 Reduced 45.1%	35,630 $1.25 Million
Q2 2021 Sep 13, 2021	BUY	$19.22 - $59.08 $1.25 Million - $3.83 Million	64,899 New	64,899 $1.39 Million

Others Institutions Holding AVIR

# of Institutions

119

Shares Held

49.6M

Call Options Held

108K

Put Options Held

327K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $306M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Atea Pharmaceuticals, Inc. Transaction History